A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients
Continue reading »
Home ยป
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
BOTHELL, Wash. and TOKYO, March 28, 2019 /PRNewswire/ — Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503,
Continue reading »
Liquid Biopsy-Based Test IDs Biomarkers in Metastatic NSCLC
FRIDAY, March 1, 2019 — A cell-free DNA (cfDNA) analysis using a 73-gene panel can successfully be used to identify
Continue reading »
Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Combination Approved for Previously Treated MSI-H/dMMR Metastatic Colorectal Cancer
PRINCETON, N.J.– July 11, 2018 (BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy
Continue reading »
TLR9 agonist CMP-001-pembrolizumab combination shows early efficacy for metastatic melanoma resistant to anti-PD-1
A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab (Keytruda), tested in patients with metastatic melanoma
Continue reading »